Why It Matters
The federal reclassification affects how medical marijuana businesses operate across the country, including potential tax relief for state-licensed dispensaries and expanded research opportunities. While recreational marijuana remains federally restricted, the shift marks the first time the federal government has officially acknowledged marijuana’s medical legitimacy.
What Happened
The U.S. Department of Justice published an order Thursday moving state-licensed medical marijuana products from Schedule I to Schedule III of the Controlled Substances Act. Acting Attorney General Todd Blanche signed the directive, which applies only to medical cannabis products authorized under state law.
The order follows a 2024 executive directive from President Donald Trump instructing the DOJ to pursue rescheduling. Blanche stated the change allows for expanded research on safety and effectiveness, giving physicians more reliable data for patient care.
Schedule I designation is reserved for substances the Drug Enforcement Administration considers highly dangerous with no accepted medical use. The new Schedule III classification places medical marijuana alongside prescription medications such as codeine-based pain relievers.
By the Numbers
Forty states and the District of Columbia currently permit medical marijuana under their laws. Twenty-four states have legalized recreational use. Previously, only cannabis grown at a single federal facility could be used for research, severely limiting available supply for scientific study.
State-licensed medical marijuana businesses could not deduct standard business expenses from federal taxes under the prior classification. The reclassification removes that restriction for qualifying operations.
What’s Next
The DEA scheduled a hearing beginning June 29 to consider broader reclassification that could address recreational marijuana. That proceeding is set to conclude no later than July 15.
The order does not resolve banking access problems for marijuana businesses. Financial institutions remain subject to potential federal money laundering prosecution for serving companies that violate federal drug statutes, even when those businesses comply with state law.
Businesses operating both medical and recreational dispensaries may face a transition period with different federal treatment for each segment of their operations. Tax benefits and regulatory requirements could diverge between medical products covered by the new order and recreational sales that remain federally prohibited.
About the Author
